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ABSTRACT(150 words)
C-reactive protein (CRP) is a major acute phase protein.  Although known to interact with chromatin, 
nucleosomes and histones, its functional roles are not clearly understood. Using both in vitro and in 
vivo models and samples from patients, this study demonstrates for the first time that CRP plays 
important roles in reducing the toxic effects of histones released into the circulation after extensive 
cell death. CRP protects endothelial cells by preventing histone integration into the cell membrane and 
thus reducing Ca2+ influx. In vivo, circulating histones cause endothelial damage, increased 
microvascular permeability, coagulation activation and IL-6 secretion. The latter induces CRP 
production in hepatocytes to form a negative feedback loop, a possible evolutionally conserved 
mechanism to limit secondary damage after extensive tissue injury.  However, CRP responses lagged 
behind the histone surge following severe trauma. This indicates a time window for histone toxicity 
and also for potential clinical interventions using anti-histone therapy.
(Word count 2999)
C-reactive protein (CRP) has long been
recognized as a major acute phase protein.
Earlier studies have demonstrated that CRP
activates complements, opsonizes pathogens 
such as Streptococcus pneumoniae and 
facilitates their clearance1,2. However, CRP is 
also upregulated in many non-infectious diseases,
such as trauma, pancreatitis, myocardial 
infarction, autoimmune diseases and cancers. 
Further studies have found that CRP binds to 
circulating nucleosomes and histones3,4. This has 
assigned a functional role for CRP in preventing 
the development of autoimmune diseases 
through clearance of nuclear breakdown 
products 5-7.
During cell death, chromatin is cleaved into 
multiples of oligo- and mono-nucleosomes, 
which are released extracellularly8 and further 
degraded into individual histones, heterodimers9
as well as free DNA10.  However, these are 
rarely detected in blood unless there is extensive 
cell death11 as they are rapidly cleared by the 
liver12. A few reports have indicated the toxic 
potential of histones. Exogenous application of 
the histone H1 induced cytotoxicity in MCF-7
cells by increasing intracellular calcium levels13.
Extracellular histones induce membrane 
permeability changes in thymus cells14.  More 
recently, the toxicity of histones to endothelial 
cells has been demonstrated both in vitro and in 
vivo15.
Here, we demonstrate for the first time that 
CRP plays an important role in the acute phase 
response to injury by reducing circulating 
histone toxicity. CRP protects endothelial cells
by forming CRP-histone complexes to block 
histone integration into the cell membrane, 
which is an essential step for histone toxicity. 
Histone integration enhances membrane 
permeability to allow Ca2+ influx, which
increases intracellular Ca2+ levels to cause cell 
damage. Resultant pathological changes include 
increased microvascular permeability and 
coagulation activation in both the animal model 
and patients with trauma, with direct correlation 
to histone concentrations. Histones also 
stimulate IL-6 release to induce CRP synthesis
by human hepatocytes. This feedback loop 
would serve to limit the secondary damage by 
histones after extensive cell death. However,
sufficient CRP elevation takes at least 4-6h
whilst histones are released immediately after 
injury. A time window therefore exists for 
potential clinical intervention to minimize the 
toxicity of acutely released histones. 
RESULTS 
Both modified and non-modified histones are 
toxic to endothelial cells 
The toxicity of histones was analyzed using flow 
cytometry based on the principle of chromatin 
loss by damaged cells16 (Fig. 1a). Toxicity of 
calf thymus histones to EAhy926 cells was dose-
dependent (Fig. 1b).  To rule out contamination, 
histone-containing solutions were extensively 
dialyzed against saline or filtered (5KD cutoff). 
Dialyzed histones remained toxic but not the 
buffer that passed through the filter. To exclude 
species variation, histones from U937, a human 
monocyte-like cell line, were isolated17 and 
found to have similar toxicity (Fig. 1b). 
Recombinant (non-modified) or isolated 
(modified) individual histones also showed 
toxicity as did H2A/H2B and H3/H4 dimers (Fig. 
1c), demonstrating that histone toxicity is not 
due to contamination by small chemicals or 
other types of nuclear proteins. 
CRP reduces histone toxicity to endothelial 
cells through complex formation
CRP, over 50 µg/ml, significantly protected
EAhy926 cells treated with 20 µg/ml histones
(Fig. 1d) and the protection reached a plateau 
from 100 µg/ml CRP.  To achieve a maximal 
protective effect, 250 µg/ml CRP (0-500 µg/ml
in patients) was used in further experiments 
unless specified (Fig. 1e). Similar results were 
obtained on primary human umbilical vein 
endothelial cells (Fig. 1e). CRP, unlike APC, did 
not cleave or degrade histones  and pre-treating 
EAhy926 cells with CRP for 1-4 h did not 
reduce histone toxicity if CRP was washed away 
prior to histone treatment (data not shown), 
suggesting that CRP protection relies on 
complex formation. Previous reports mainly 
used I125-labeled CRP and demonstrated that 
CRP interacted with H1, H2B and H3 but not 
H43,4,18. Our gel overlay assay showed a similar 
pattern (Fig. 1f). However, when CRP or 
individual histones were immobilized on an 
optical biosensor, both H4 and H3 showed far 
stronger binding to CRP than H1, H2A and H2B 
(Fig. 1g&h). It was reported that CRP cross-
links only to H4 in solution19. These 
discrepancies may be due, in part, to limitations 
of the detection methods used. In fact, CRP
bound to all tested histones and accordingly 
protected EAhy926 cells treated with H1, H2A,
H2B, H3 or H4 (p<0.05) (Fig.1i). 
CRP blocks histone integration onto the cell 
membrane, which is an essential step in 
inducing toxicity
As to the mechanism(s) involved in histone 
toxicity, the available literature points to a
histone-induced increase in membrane 
permeability20. FITC labeled-histones in culture 
medium started to enrich in endothelial cell 
membranes after 10 min incubation (Fig 2a, A-
C). Pre-incubated with CRP, FITC-histones 
aggregated in the culture medium or inside cells 
but did not concentrate on the cell membrane 
(Fig. 2a, D-F). Since anti-histone antibodies can
reduce histone toxicity15, we produced an anti-
histone recombinant antibody (ahscFv) which 
strongly binds to H1, H3 and H4 but weakly to, 
H2A and H2B (Supplemental Fig. 1) for 
confirming the specificity of CRP effects on 
histones. Here, ahscFv showed similar effects to
CRP (G-I), confirming CRP directly affects 
histones but not the cell membrane. Truncated 
histones lost their toxicity once their membrane 
binding properties14 were disrupted 
(Supplemental Table 1). However, deletion of 
H1 N-terminal 110 amino acids (aa), H2A C-
terminus 68aa or H3 C-terminal 62aa did not 
block their membrane binding and toxicity.
APC-cleaved FITC-histones increased their 
internalization but reduced membrane binding 
and toxicity (Supplemental Fig. 2). These data 
strongly suggest that histones inside cells are not 
toxic whilst membrane binding is essential to
their toxicity, at least to endothelial cells.
Histone binding to the cell membrane causes 
hyper-permeability to ions, which is inhibited 
by CRP
Whole-cell currents were recorded using the 
perforated patch configuration from single 
EAh926 cells, as previously described21.
Histones induced large dose-dependent inward 
currents that were reversible for short exposure 
times (Fig 2b). The development of inward 
current indicates a net influx of positively 
charged ions, such as Ca2+ and Na+, or the efflux 
of negatively charged ions, such as Cl-. We 
found that intracellular Ca2+ was elevated to 50, 
200 and 1000 nM after exposure to 10, 20 and 
50 µg/ml histones, respectively (Fig. 2c). The 
elevation was abolished when extracellular Ca2+
was removed (Fig. 2d), indicating that Ca2+
influx is the major cause.   It is well known that 
a sustained increase in cytosolic Ca2+ can lead to 
cell death in many cell types22-25.  By controlling 
the extracellular Ca2+ concentration, we found 
that the extent of histone-induced cell damage 
positively correlated to extracellular Ca2+
concentrations (2e).  Pre-incubating histones 
with CRP or ahscFv dramatically suppressed 
both inward whole cell currents (2f) and 
intracellular Ca2+ elevations (2g) (Supplemental 
Fig. 3) and suggests Ca2+ influx as the 
downstream cause of histone toxicity.
CRP reduces histone-induced endothelial 
permeability both in vitro and in vivo
Elevation of intracellular Ca2+ is involved in the 
pathway used by inflammatory factors, e.g.
thrombin, to induce permeability changes26.
Histones increased permeability of an 
endothelial monolayer in a dose-dependent 
manner (Fig. 3a). A significant change occurred 
after 40 min exposure to 20 µg/ml histones (Fig. 
3b), which is later than that induced by thrombin
(within 10 min) and suggests that their 
mechanisms may differ. CRP, APC and ahscFv 
abolished the increased endothelial permeability 
induced by 20-50 µg/ml histones (Fig. 3c). All 
individual histones significantly increased
permeability (Fig. 3d). To confirm that 
circulating histones are able to increase vascular 
permeability in vivo, the ratio of wet/dry weights 
of lung were monitored27. A sublethal dose, 50
mg/kg histones significantly increased the ratio 
(p<0.05), which was also inhibited by co-
injection of 10 mg/kg CRP or ahscFv (p<0.05)
(3e). 
CRP protects histone-treated mice 
Intravenous injection of 50 mg/kg histones or 
CRP alone did not kill any mice. Injection of 75
mg/kg histones killed all mice within an hour.
When low-dose CRP (1.6 mg/kg) was co-infused 
with histones (75 mg/kg), survival times were 
prolonged. When CRP was increased to 5 mg/kg,
2/6 mice survived for over 6 days and 4/6 mice 
died between 7-11 h after injection. With 10
mg/kg CRP, 7/7 mice survived for over 6 days 
(Fig. 3f). Log-rank test showed significant 
differences in the survival times between the 4 
groups (p<0.001). Ten mg/kg ahscFv had the 
same protective effect. Histological examination 
showed multifocal alveolar hemorrhage and 
edema with capillary microthrombi in lungs and 
kidneys of the histone alone group (Fig. 3g, 
A&B) to indicate increased microvascular 
permeability and coagulation activation.
Similarly, mice euthanized 4 h after injection of 
75 mg/kg histones+10 mg/kg CRP (panel C) or 
10 mg/kg ahscFv (panel D) showed lung
congestion and edema but much less lung 
hemorrhage.  No capillary microthrombi were 
observed in these animals. Sections from mice 
euthanized at 24 h (panel E) and 6 days (panel F)
after sublethal dose of histones (50 mg/kg) 
showed numerous neutrophils within lung 
capillaries (E, arrows) and perivascular rim of 
macrophages with fewer lymphocytes (F, arrow). 
Both exogenous and endogenous histones
damage endothelial cells and activate 
coagulation in vivo, which is inhibited by CRP
Immunohistological staining showed that 
injected histones accumulated in the membrane 
of endothelial cells. Faint staining was also 
found on the membrane of blood cells (Fig. 4a, 
panel A) but no such staining was found in 
control mice (panel B). In histones+CRP groups,
histone accumulation in the endothelial 
membrane became less obvious (panel C). To 
demonstrate histone-induced endothelial damage 
and coagulation activation in mice, levels of 
soluble thrombomodulin (sTM), an endothelial 
cell membrane protein which can be shredded 
and released upon cell damage28, and TAT, a 
recognized marker of coagulation activation29
were measured. sTM and TAT increased about 2 
fold in 50 mg/kg histones+saline group 
compared to saline alone. When histones were 
pre-incubated with 10 mg/kg CRP and then 
injected into mice, sTM and TAT levels became
significantly lower than in the histones+saline 
group (Fig.4b, c). To explore the effect of 
endogenous histones, we established a modified 
mice model of severe trauma based on previous 
reports30 by dropping a heavy object onto each 
leg of anesthetized mouse. H3 was detectable
after trauma (Fig. 4d). The levels in 
trauma+saline (CRP-) group and trauma+CRP
(CRP+) group were not significantly different
(4e) but sTM and TAT levels were significantly 
higher in trauma+saline group than that in 
control and trauma+CRP groups (P<0.05)(Fig. 
4f&g), indicating that endogenous histones 
released from tissue injury was similar to 
exogenous histones in causing endothelial cell 
damage and coagulation activation, which can be 
inhibited by CRP. 
Extensive cell death in trauma patients 
elevates circulating histones to levels that 
exceed neutralization in blood
Levels of circulating nucleosomes of 250 trauma 
patients (Supplemental Table 2) on admission
were associated with severity estimated by injury 
severity scores (ISS) (Fig. 5a).  Western blotting, 
determined the levels of non-degraded histone 
H3 (Fig. 5b) from which the total circulating 
histones could be estimated. In patients with 
major trauma, the calculated total circulating 
histones ranged from 10 to 230 µg/ml within 4h
after injury with Median: 28.6, Quartile: 13.7,
58.9 µg/ml in a group of 52 major trauma 
patients. When applied in DMEM medium, 10
µg/ml histones showed significant toxic effects
on cultured endothelial cells. When applied in 
serum or plasma (using PPACK, a non-calcium 
chelating anticoagulant31) these effects were not 
evident until histones reached 20 and 40 µg/ml,
respectively, suggesting normal blood could 
neutralize at least 10-30 µg/ml histones.
Components in serum and plasma that neutralize 
histones are not clear. Patients had significantly 
higher sTM (Median: 4600.3 Quartile: 3648.6, 
5497.1 pg/ml) and TAT (Median 81.2, Quartile 
33.7, 110.3 ng/ml) than healthy donors (sTM 
Median: 2389.3 Quartile: 1123.1, 3011.9 pg/ml, 
TAT Median: 6.0 Quartile: 5.6, 6.4 ng/ml, n=20)
(Median test, P<0.01). Although the correlation 
between H3 and ISS was poor (Fig. 5c, r=0.36, 
p<0.05), the levels of sTM and TAT in the 52 
trauma patients were well correlated to 
circulating histones (Fig. 5d&e, r=0.55 and 
r=0.56, P<0.001). These results are consistent 
with the finding in animal experiments and 
suggest that in trauma patients, high levels of 
circulating histones are toxic. 
Complexes between CRP and circulating 
histones limit damage to endothelial cells in 
patients
Further dynamic analysis of a group of 7 patients 
with simple blunt injury showed that circulating 
nucleosomes and histones sharply increased on 
admission and were significantly reduced to 20-
30% of original levels by 72 h after injury (Fig.
5f). CRP levels started to increase at 4-6 h after 
injury to peak at around 24 h. At this time, CRP-
histone complexes became detectable (Fig. 5f). 
This data indicates that CRP elevation lagged at 
least 4 h behind the histone surge. Serum
containing about 50 µg/ml histones collected 
within 4 h after injury was toxic to cultured 
endothelial cells (Fig. 5h), which could be
neutralized by adding CRP and ahscFv, or 100
nM APC (Fig 5g). This suggests that the toxicity 
comes from histones within these sera. In 
contrast, sera collected after 24 h, which 
contained both high levels of histones (rebound 
after surgery) and CRP showed no significant 
toxic effects. Similar results were obtained with 
sera from patients with severe sepsis and 
necrotizing pancreatitis (Data not shown).    
These observations support the idea that 
endogenous CRP elevation neutralizes the toxic 
effects of circulating histones in many clinical 
scenarios.
IL-6 secretion triggered by circulating 
histones induces CRP production in a
feedback mechanism
We noticed that levels of circulating histones 
were positively correlated to IL-6 (Fig. 6a) and 
IL- 	

	   in trauma patients
but the latter only increased significantly in a
few patients. Since IL-6 is the essential regulator 
of CRP expression in hepatocytes32,33, this 
observation suggests that an IL-6-mediated link 
between histones and CRP exists. Previous 
reports show that T lymphocytes, endothelial 
cells, macrophages and neutrophils secrete IL-634.
In trauma, IL-6 reached a peak value around 2h
after injury35 which suggests that pre-synthesized
IL-6 was released from storage. We found that
isolated leukocytes from human peripheral blood 
released high levels of IL-6 from 2h after 
stimulation with 50 µg/ml histones (Fig. 6b) and
the release was inhibited by 100 µg/ml CRP (Fig.
6c). Medium containing the released IL-6
stimulated CRP production in hepatocytes (Fig.
6d). Intravenous injection of histones into mice 
stimulated IL-6 release, which peaked at 4h (Fig. 
6e). Similarly, IL-6 was significantly increased 
in the trauma model (Fig. 6f). Flow cytometry 
showed that IL-6 existed in lymphocytes, 
neutrophils and monocytes from healthy donors 
(6g). Immunohistochemical staining showed that 
IL-6 was positive in normal mouse blood cells 
and bronchi epithelial cells (Fig. 6h). These data
demonstrate that circulating histones are major 
factors in stimulating IL-6 release in trauma to 
trigger CRP production and also explain why IL-
6 increase is in proportion to the magnitude of 
the surgical stress36. The data also suggest that a 
physiologically relevant negative feedback loop 
exists (Fig. 6i), which could have an important
impact on the survival from trauma or other 
diseases accompanied by extensive cell death or 
tissue injury.
DISCUSSION
Elevation in CRP levels has long been 
recognized as a non-specific response to many 
pathological situations, including infection, 
inflammation, neoplasm and injury. Here we 
demonstrate for the first time that the generic 
role of CRP is to combat the toxicity of histones 
released after extensive cell death. CRP 
elevation in trauma is a direct response to 
circulating histone-stimulated IL-6 secretion and 
is able to reduce secondary damage by forming 
CRP-histone complexes.
It is reported that histones bind to different 
phospholipids37-40, which are major components 
of the cell membrane. Here, we confirm that 
histone integration into the cell membrane and 
the resultant Ca2+ influx are the major 
mechanism of histone toxicity to endothelial 
cells. CRP, APC and ahscFv protect these cells 
by reducing histone-membrane interaction.  
Evidence of endothelial damage in vivo by 
both exogenous and endogenous histones is 
provided by the elevation of sTM. Increased 
endothelial permeability is another indicator. In 
histone-treated mice, lung oedema, haemorrhage,
and increased wet/dry lung weight ratio reflect 
the vascular permeability changes. Thrombosis 
and elevated TAT levels may be partly due to 
endothelial damage. However, other factors, 
such as impairing protein C activation41, histone-
induced neutrophil extracellular traps (NET)42
and platelet activation41,43,44 (Supplemental Fig. 5, 
6) are also involved. AhscFv but not CRP is able 
to inhibit H3 or H4 induced-platelet aggregation
and suggests that the mechanism for histone-
induced platelet activation is different from that 
of histone-induced endothelial damage. This 
differential rescue effect of CRP might be 
helpful in not compromising the histone-induced 
haemostatic response to injury whilst dampening 
histone damage to endothelial cells, in particular.
CRP and APC are the currently known natural 
molecules with anti-histone properties. Their 
circulating levels are low in healthy adults but 
CRP can increase 1000 fold to reach 500 µg/ml
in the acute phase of many diseases. Protein C
levels can decrease in conditions, such as severe
sepsis. We also noticed that CRP elevation is
mediated by IL-6, which directly responds to the 
increase in circulating histones. Therefore, CRP 
elevation in acute phase responses represents a
powerful mechanism in humans to combat the 
toxicity of circulating histones. 
Although circulating histone levels in patients 
with trauma did not reach the concentrations
used in mice to induce lethality, their levels far
exceeded the normal blood capacity to neutralize 
histone toxicity. As observed, histone-induced 
secondary injury occurred and may promote 
organ failure by damaging endothelial cells, 
increasing micro-vascular permeability and
activating blood coagulation. We noticed that in 
the acute phase of severe trauma, nucleosomes 
and histones are released immediately after 
tissue injury while it takes up to 6 h or more for 
CRP to rise to active levels45. This indicates a
time window for histones to exert their toxic 
effects before they are neutralized by CRP.
Therefore, a potential critical time period for 
clinical intervention exists for anti-histone 
therapy. From a therapeutic standpoint, APC is 
an anti-coagulant with bleeding as a major side 
effect and this would prevent its use in many 
acute injury states. CRP activates the 
complement system, which might cause further 
tissue damage. The potential is there for specific 
anti-histone therapy and in this study, we have 
developed an ahscFv (Supplemental Fig. 1)
which protects cultured endothelial cells and 
mice exposed to histones. Further optimization 
to improve efficacy and reduce possible side 
effects could hold promise and provide hope for 
much needed solutions in the acute management 
of severe trauma and life-threatening injuries.
ONLINE METHODS
Tissue culture. EAhy926 (human endothelial), 
Hep3B (human hepatocytes from ATCC) and 
U937 (human monocytic) cell lines was cultured 
in Dulbecco's Modified Eagle Medium (DMEM, 
Sigma) supplemented with 20% Fetal Bovine 
Serum (FBS, Sigma). Human umbilical vein 
endothelial cells (HUVECS) were isolated as 
described previously46. The detached cells were 
cultured in DMEM medium supplemented with 
20% FBS and 5 ng/mL epidermal growth factor 
(Invitrogen) and used within 3 passages. 
Reagents. Human CRP (Merck) proteins were 
extensively dialyzed and concentrated. After 
confirmation of the pentamer form of each 
protein by HPLC gel filtration, CRP at final 
concentrations of 1, 2 or 4 mg/ml was stored at -
80oC. Anti-histone scFv was expressed in E. coli 
and purified using his-binding resin. LPS 
contamination was also monitored using E-
ToxateTM reagents (Sigma). Similarly, 
recombinant histones (New England Biolab) and 
calf thymus histones (Roche) were also 
monitored using E-ToxateTM.  Any reagents with 
LPS over 0.1 EU/mg were passed through a
Detoxi-GelTM column (Pierce) to remove LPS 
and reconfirmed as LPS-free prior to use. 
Isolation of human histones. Histones were 
isolated from the human monocytic U937 cell 
line using the acid extraction method 17. Isolated 
histones were concentrated using a Vivaspin 
protein ultrafiltration device (5,000 MWCO) 
(Sartorius Stedim biotech) and their purity 
ascertained by 15% SDS/PAGE stained with 
Coomassie Brilliant Blue. H1, H2A, H2B, H3 
and H4 migrated with correct molecular weights 
and the overall purity was over 95%. The 
preparation did not contain detectable LPS and 
other nuclear proteins.
Gel overlay assay. Equal amount of proteins (3
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-PAGE. One gel was 
stained with Coomassie Brilliant Blue to check 
equal loading and the other gel were electro-
blotted onto PVDF membranes, which were then 
incubated at 4oC overnight with biotinylated 
CRP. The CRP bound to histones was detected 
using streptavidin –HRP (Sigma).
Binding assays using a biosensor. Binding 
reactions were carried out in an IAsys two-
channel resonant mirror biosensor (Affinity 
Sensors), as described previously47; CRP 
purified from human ascites (Merck) was 
immobilized on aminosilane surface using BS3
(Perbio, Chester, UK). One of each class of 
human recombinant histones was applied to the 
surface and the binding curves recorded.   The 
recombinant histones were also immobilized on 
aminosilane surfaces separately and 5.5 	 
CRP in solution was applied. This is to ensure its 
pentameric form during the binding assays and 
to rule out the possibility that pentameric CRP 
may be interrupted during immobilization and 
surface regeneration.
Histone cytotoxicity assay. A propidium iodide 
method was used, as previously described16.
Briefly, EAhy926 cells were grown to 70-90% 
confluence in 24-well plates. Cells were washed 
with PBS and then incubated with histones with 
or without human CRP in DMEM (Sigma) 
medium supplemented with 2% FBS, for 1 h 
under 5% CO2 at 37°C.  When histones and CRP 
or APC was used, treatments were prepared 30 
minutes prior to incubation with the cells.  After 
1 h incubation, cell supernatant was removed 
and cells were detached with Versene (GIBCO).  
Cells and supernatant were then combined and 
washed twice in PBS (Fisher Scientific 
International Inc.) and fixed in 70% ethanol for 
30 min at -20C.  Cells were then centrifuged at 
500g for 5 min and stained with propidium 
iodide (final concentration of 20 µg/ml).  Flow 
cytometric analysis of propidium iodide-stained 
damaged nuclei results in a broad peak of 
hypodiploid particles, clearly separated from the 
distinct diploid DNA peak of viable cells.
Permeability assay. The permeability of a 
confluent monolayer of endothelial cells was 
analyzed in a dual chamber system using Evans 
blue-labeled BSA, as described previously48. In 
brief, 100 µl (5x105) EAhy926 cells were seeded 
on the upper chamber of Transwell 
polycarbonate membranes (24 well, 
Polycarbonate filters, 0.4 
!
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and the lower chambers filled with 500 µl of 
DMEM (supplemented with 20% FBS), cells 
were then grown for 2 days at 37C to obtain a 
monolayer. Permeability was assessed by 
replacing the media in the upper chamber with 
100 µl Evans Blue-BSA (0.67 mg/ml Evans blue 
in DMEM containing 4% BSA) and in the lower 
chamber with 500 µl media (DMEM 
supplemented with 4% BSA). After 10 min, a 
100 µl aliquot was taken from the lower chamber 
and absorbance measured at 650nm using a 
spectrometer. 
FITC labeling and confocal microscopy. The 
histones were labeled using FluoroTagTM FITC 
conjugation kit (Sigma) according to the 
manufacturer’s instructions and free FITC was 
separated from FITC-proteins using sephadex 
G25 column. The FITC- labeled protein was 
added into cultured EAhy926 cells to a final 
concentration of 10 µg/ml on a 35 mm glass-
bottomed dish. The images were taken using 
LSM 710 confocal microscopy. 
Electrophysiology. Whole-cell currents were 
recorded using the perforated patch 
configuration from single EAhy926 cells using 
an Axopatch 200B amplifier (Axon Instruments) 
as previously described49,50 Recorded membrane 
currents were filtered at 5 kHz, digitized using a 
Digidata 1320A interface (Axon Instruments) 
and analyzed using pCLAMP software. Patch 
pipettes were pulled from borosilicate glass 
capillaries (outer diameter 1.5 mm, inner 
diameter 1.17 mm; Harvard Apparatus) and fire-
polished to giv
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
   $ % &
when filled with pipette-filling solution 
containing 210 µg/ml Amphotericin B (Sigma-
Aldrich). Histones (20 µg/ml), CRP (250 µg/ml)
and/or anti-histone scFv (250 µg/ml) were added 
to the extracellular solution and applied to the 
cell by bath superfusion. Histones were 
incubated with CRP or antibody for at least 30 
minutes prior to application to the cells.  All 
experiments were performed at room 
temperature (18–22°C), and the results are 
expressed as the mean ± S.E.M. 
Measurement of intracellular calcium. 
Intracellular calcium concentration [Ca2+]i was 
determined by measuring fluorescence emission 
at 510 nm during excitation at 340 nm and 380 
nm according to a published protocol51 and Fura-
2AM as a fluorescent probe. EAhy926 cells were 
loaded with 3 µM Fura-2AM for 20 min and 
then washed with Calcium Assay Buffer (pH7.4) 
(120 mM NaCl, 4.7 mM KH2PO4, 1.2 mM MgCl, 
1.25 mM CaCl2, 10 mM Glucose, 20 mM Hepes). 
Fluorescence was monitored continuously using 
a Hitachi F-7000 fluorescence spectrometer, and 
[Ca2+]i was calculated using the software 
provided with the instrument. Ca2+ influx was 
stimulated in EAhy926 cells with the addition of 
calf thymus histones (Roche) or recombinant 
human histones to the Fura-2 loaded cells.
Animals. C57/BL6 male mice of average weight 
~22g from the SLAC Experimental Animal 
Centre (Shanghai, China) were kept and used at 
the Research Center of Gene Modified Mice, 
State Education Ministry Laboratory of 
Developmental Genes & Human Diseases, 
Southeast University, China. All procedures 
were performed according to State laws and 
monitored by local inspectors. This is also in 
compliance with British Home Office laws. 
Immunohistochemical staining. Paraffin-
embedded samples on glass slides were de-
waxed and rehydrated followed by antigen 
retrieval using DAKO PT-Pre-Treatment link 
system at 97°C. After blocking any endogenous 
peroxidase activity, the sections were incubated 
with anti-histone H3 antibody (Abcam) diluted 
1:100, and anti-IL-6 (R&D) 1:50 for 2 hours. To 
confirm their specificity, these antibodies were 
preincubated with histone H3 or IL-6 protein 
(molar ration 1:2) and secondary antibody alone 
as controls to validate each lot of staining. After 
washing, anti-rabbit secondary antibody-HRP 
labeled polymer (DAKO EnVision+ System-
HRP (DAB) kit), was applied to the slides and 
incubated for 30 min. The bound antibody was 
visualized using DAB+chromagen for 1-5 min, 
followed by counterstaining with Mayer’s 
haemalum and soaking in lithium carbonate 
(Sigma-Aldrich),   After dehydration, the slides 
were mounted with coverslips using DPX (BDH) 
mountant and left to dry overnight. Images of the 
stained samples were taken using Olympus 
Microscopy and Nikon ACT-1 software.
In vivo permeability assay. Wild type C57BL/6
male mice of 22 gram body weight were 
challenged with 50 mg/kg histones (i.v.),
histones+10 mg/kg CRP, and histones+10 mg/kg 
anti-histone scFv for 4 h.  Pulmonary edema was 
quantified by measuring the wet to dry weight 
ratio of the right lung.  Wet weight is obtained 
immediately after extirpation and dry weight 
after 4 days of drying at 60°C. For histological 
analysis the cardiac lung lobe was formaldehyde 
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microsections were analyzed by HE staining.  
Mouse trauma model. The mouse trauma 
model was created by the fall of heavy object to 
4 limbs of anesthetized mice according to 
previous reports30. Blood was taken with citrate 
as anti-coagulant from tail veins before and 60
min, 4 h after injury. The plasma was separated 
by centrifugation and stored at -80oC before 
analysis. The mice were euthanized at 4 h and 
organs were taken and fixed by 4% 
paraformaldehyde for 24 h followed by 70% 
ethanol.
Quantification of nucleosomes, histones, 
histone-CRP complexes, CRP, sTM, TAT, IL-
6, and IL- in patient plasma. To quantify the 
amount of circulating nucleosomes in patients, a 
Cell Death Detection ELISAPLUS assay (Roche 
Diagnostics) was used according to 
manufacturer’s instructions.  The assay for 
nucleosomes (histone-DNA complexes) is based 
on a quantitative sandwich-ELISA whereby two 
monoclonal antibodies generated against DNA 
(single and double stranded) and histones (H1, 
H2A, H2B, H3 and H4) capture mono- and 
oligo-nucleosomes. For histone-CRP complexes, 
the same kit was used by replacing anti-DNA 
antibody with HRP-conjugated anti-CRP 
monoclonal antibody.  The CRP ELISA kit was 
from DiaMed. ELISA kits for sTM and TAT 
were purchased from Cusabio Biotech. ELISA 
kit for IL-6 and IL- 

   )*
+
Each sample was performed in duplicate.
Histone H3 in plasma were detected by Western 
blotting using anti-histone H3 antibody (Abcam) 
and calculated using human recombinant histone 
H3 protein (New England Biolabs) as standards.
Whole blood flow cytometry analysis. To 
identify the population of IL-6 containing white 
blood cells, 100 	 ,	
	

at room temperature for 15 minutes with 200 	
of Fixation Medium (Fix&PermReagent A, 
AN GRUB, Austria) then washed in 10 mls PBS 
by centrifugation for 5 min at 300g.  The cells 
were then resuspended in 200 	
Permeabilization Medium (Fix&PermReagent 
B, AN GRUB, Austria) and incubated at room 
temperature for a further 15 min.  Cells were 
then washed in 10 ml PBS and centrifuged for 5 
min at 300g.  The white blood cell pellet was 
then resuspended in 100 	-.  %/
BSA and either 0.5 Rat Anti-Human IL-6-PE 
(BD Pharmingen™, UK) or Normal Rat IgG-PE 
antibody control.  After 30 min incubation the 
cells were washed twice in 100 	 -. ,

resuspended in 100 	 -.   

 flow 
cytometric analysis.  To identify the neutophil,
monocyte and lymphocyte populations, cells 
were stained with Anti-Human CD15-FITC (BD 
Pharmingen™, UK), Anti-Human CD14-FITC 
(BD Pharmingen™, UK) and Anti-Human CD3-
FITC (BD Pharmingen™, UK), respectively. 
Statistical analysis. Intergroup differences were 
analyzed using ANOVA followed by the 
Student-Newman-Keuls test. Two group 
comparison before and after treatment used 
Student t test. Animal survival time was 
analyzed using log-rank test. Association 
analysis used simple linear correlation.
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Figure legends 
Figure 1. The toxicity of histones to cultured 
endothelial cells can be inhibited by CRP 
through CRP-histone complex formation. (a)
Typical FACS of untreated and histone-treated 
EAhy926 cells after PI staining, 2N represents 
intact surviving cells after treatment and <2N 
represents cells that have lost chromatin and 
designated as non-surviving cells (Materials and 
Methods). (b) Survival rate of EAhy926 cells
after various treatments. Mean±SD from at least 
3 independent experiments are shown. ANOVA 
tests show that calf thymus histones, dialyzed 
calf thymus histones and human histones cause 
significant damage of EAhy926 cells (p1 0.03) 
while BSA or acid-treated BSA had no harmful 
effect on these cells (p2 0.2). (c) Toxic effects of 
individual human recombinant (hr)/calf thymus 
(cth) histones and calf thymus H2A/H2B and 
H3/H4 complexes on cultured EAhy926 cells. 
Cells were treated with 20 µg/ml mixed histones 
from calf thymus as a control and 20 µg/ml of 
individual histones or complexes (10 µg/ml of 
each component). Mean ±SD of cell survival 
rates from at least 3 independent experiments are 
shown. *indicates significant reduction of cell 
survival rates after treatment (p<0.05).  (d) Dose 
response of CRP in protecting EAhy926 cells 
treated with 20 µg/ml calf thymus histones. 
Means±SD of cell survival rates after treatment 
from 3 experiments are shown and ANOVA test 
showed that CRP significantly increased cell 
survival rates (p<0.05). (e) Protective effects of 
CRP and APC on both HUVECS and EAhy926 
cells treated with histones. Both types of cells 
were cultured to 70-80% confluence and treated 
with calf thymus histones 20 µg/ml alone or in 
combination with APC 10 nM or CRP 250 
µg/ml as described in Materials and Methods. 
Means±SD from 3 independent experiments are 
showed. *indicates a significant reduction of cell 
survival rates compared with untreated cells (UT) 
(p<0.05). (f) Gel overlay assay to study CRP 
interaction with immobilized histones (Materials 
and Methods). Upper panel: gel overlay shows 
that CRP binds to H1, H2B and H3. Lower panel: 
Coomassie blue stained gel (n=S100P multimer, 
m=S100P monomer).  (g) and (h) Biosensor 
assay to study interaction between histones and 
CRP. CRP (g) or individual histones (h) were 
immobilized on biosensor surfaces as described 
in Material and Methods. Binding curves of each 
human recombinant histone presenting their 
relative binding strengths to immobilized CRP or 
vice versa are shown in (g) and (h), respectively. 
(i) CRP protection of EAhy926 cells treated with 
20 µg/ml individual human recombinant histones. 
Percentages of cells (means±SD) rescued by 250 
µg/ml CRP from 4 independent experiments are 
shown, i.e. cell survival rate differences between 
cells treated with histones alone and histones 
+CRP. *indicates significant increases of cell 
survival rate by CRP addition (p10.035, Student 
t test).
Figure 2. Membrane binding and calcium 
influx determine histone toxicity to 
endothelial cells and could be inhibited by 
CRP. (a) Confocal images of EAhy926 cells 
incubated with FITC-histones (10 µg/ml) (panels 
A-C), FITC-histones+CRP (250 µg/ml) (panels 
D-F) and FITC-histones+anti-histones scFv (250
µg/ml) (panels G-I). Panels A, D, and G are F 
show FITC staining (green), panels B,E and H 
are phase contrast and panels C,F and I are the 
superimposed images of FITC and phase 
contrast. Arrows indicate membrane binding of 
FITC-histones. (b) Representative whole-cell 
currents recorded from EAhy926 cells when 
histones (20 µg/ml) were applied to the 
extracellular bathing solution as indicated. The 
currents generated by the application of histones 
were reversible on short exposure (30–60 
seconds). (c) An example of elevation of 
intracellular Ca2+ recorded by Hitachi F-7000
fluorescence spectrometer when EAhy926 cells 
were exposed to different concentrations of 
histones. (d) An example of intracellular Ca2+
elevation triggered by histones (20 µg/ml) that 
was nearly abolished by removal of Ca2+ from 
extracellular medium. (e) The mean±SD of 
survival rates of cells incubated with medium 
containing 0-3 mM Ca2+ in the presence or 
absence of 20 µg/ml histones from 3 
independent experiments. *indicate significant 
reduction of cell survival rate compared to that 
without calcium (ANOVA test P<0.05) (f) and 
(g) show the inhibitory effects of CRP (250
µg/ml) and anti-histone scFv (250 µg/ml) on
histone-induced whole cell current and 
intracellular Ca2+. Mean±SD from 3 independent 
experiments are shown. *indicate significant 
increase compared to all other groups. 3
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significant lower compared to histone alone 
(P=0.021) but significantly higher than the rest 
of groups (P<0.05). 
Figure 3. CRP reduces histone-enhanced
endothelial permeability and protects mice 
injected with lethal dose of histones. (a) 
Endothelial permeability changes measured by a
dual chamber system using Evans blue-labeled
BSA when confluent EAhy926 cells were treated 
with 0-50 µg/ml histones. Mean±SD of 
absorbance from 5 independent experiments are 
shown. * indicate significant increase of 
permeability compared to untreated cells 
(P<0.05). (b) the time course of 20 µg/ml 
histone-induced permeability changes. 
Mean±SD of absorbance from 5 independent 
experiments are shown. * indicate significant 
increase of permeability (P<0.05). (c) The 
inhibitory effects of APC, CRP (250 µg/ml) and 
anti-histone scFv (250 µg/ml) on 20 µg/ml 
histone-induced permeability increase. 
Mean±SD of fold changes to untreated (UT) 
from 3 independent experiments are 
shown.*indicates significant increase compared 
to all other groups. (d) the fold changes of 
endothelial permeability induced by different 
histones (2 µM). Mean±SD of fold changes to 
untreated from 3 independent experiments are 
shown. *indicate significant increase compared 
to untreated (ANOVA test, P<0.05).  (e) the 
dry/wet weight ratios of lungs from the mice (10 
mice in each group) euthanized  4 h after 
intravenous injection of with saline (control), 50 
mg/kg histones, histones+10 mg/kg CRP or anti-
histone scFv.  * indicate significant increase in 
ratio, caused by fluid leakage into lungs 
(ANOVA test, P<0.05). (f) Survival curves 
represent the survival fractions of mice injected 
intravenously with 75 mg/kg of histones (group 
1, n=5), 75 mg/kg histones + 1.6 mg/kg CRP 
(group 2, n=4), 75 mg/kg histones + 5 mg/kg 
CRP (group 3, n=6) and 75 mg/kg histones + 10
mg/kg CRP (group 4, n=7). (g) histological 
changes in mice after treatment with histones 
and CRP. Haematoxylin staining of sections 
from mouse that died after injection with 75 
mg/kg histones: lung (panel A) and kidney 
(panel B) showed microthrombi in lung 
capillaries and glomerular tufts, respectively 
(arrows). Mice euthanized 4 h after injection of 
histones (75 mg/kg) + CRP (10 mg/kg) (Panel C) 
or anti-histone scFv (Panel D) showed lung 
congestion and edema (arrows) but no 
microvescular thrombi.  Sections from mice 
euthanized at 24 h (panel E) and 6 days (panel F)
after non-lethal dose of histones (50 mg/kg) 
showed numerous neutrophils within lung 
capillaries (arrows) (panel E) and perivascular 
rim of macrophages with fewer lymphocytes 
(arrow) (panel F). Bar =20 µm.
Figure 4. High levels of exogenous and 
endogenous circulating histones cause 
endothelial damage and coagulation 
activation. (a) Immunohistochemical staining of 
histone H3 in tissues from mice injected 
intravenously with saline (left), 50 mg/kg 
histones (middle) and histones+CRP (10 mg/kg) 
(right). Red arrows indicate the nuclei of 
endothelial cells and blue arrows indicate the 
association of histones with the plasma 
membranes of endothelial cells. (b) and (c) show 
the levels of circulating sTM and TAT in mice 
(10 mice per group)  injected with saline 
(control), CRP (10 mg/kg), histones (50 mg/kg) 
and CRP+histones. Mean±SD are shown. 
*indicates significant increase when compared to 
other groups (P<0.05, n=6/group). (d-g) Mice 
trauma model (10 mice per group).  (d) An 
example of western blotting of histone H3 in the 
plasma taken from mice before (1) and 1 h (2), 4 
h (3) after trauma or anesthetics only (Control). 
In CRP+trauma group, 10 mg/kg CRP was 
intravenously injected 10 min before trauma. (e) 
Averages of histone H3 determined by Western 
blotting. No significant difference between CRP-
and CRP+ groups but significant increase in both 
groups after trauma. (f) and (g) show the
changes of sTM and TAT in circulation. 
Mean±SD are shown. *indicate a significant 
increase (P<0.05) compared to other groups.
Figure 5. The levels and dynamic changes of
circulating histones and CRP in patients with 
severe trauma. (a) The levels of circulating 
nucleosomes at admission measured using 
ELISA kit were significantly increased with the 
severity of trauma estimated by ISS in a group of 
250 patients (Supplemental Table 2). *ANOVA 
test, P<0.05). (b) an example of a Western blot 
measuring the levels of full length histone H3 in 
the plasma of trauma patients. The standard H3 
recombinant protein was from New England 
Biolabs. (c) correlation between H3 and ISS in a 
group of 52 patients (r=0.36, P<0.01). (d) and (e) 
correlation of H3 with sTM (r=0.55, P<0.001) 
and TAT˄r=0.56, P<0.001˅in the same group 
of patients. (f) dynamic changes of Histone H3, 
CRP and CRP-histone complexes in  a group of 
7 trauma patients. The highest values of each 
parameter were designated as 100%. The 
absolute values were presented in Supplemental 
Fig. 7. (g) The toxic effect of sera (50% in cell 
culture medium) taken at different time points 
from a group of 7 trauma patients on cultured 
endothelial cells, EAhy926. The mean±SD are 
shown. * indicate a significant reduction 
compared to normal (ANOVA test, P<0.05). (h) 
Serum containing about 50 µg/ml histones 
(estimated by H3) taken at admission was 
incubated with EAhy926 cells (50% serum in 
medium alone, or supplemented with 100 nM 
APC, 250 µg/ml CRP, and 200 µg/ml anti-
histone scFv). Cell survival rates are presented. 
*indicate significant reduction when compared 
with other groups (ANOVA testˈ P<0.05).
Figure 6. Circulating histones trigger the 
release of IL-6 and subsequently induce CRP 
production. (a) Circulating IL-6 significantly 
increased in severe trauma and correlated with 
circulating histone H3 in a group of 52 patients 
(r=0.61, P<0.001). (b) and (c) histones  
stimulated IL-6 release from isolated leukocytes. 
Blood was taken from 3 healthy donors and the 
leukocytes were isolated using gradient 
centrifugation and cultured in DMEM medium 
containing 20% FBS in the absence (UT) and 
presence of 50 µg/ml histones, 250 µg/ml CRP, 
5 nM LPS or histones+CRP. Mean levels of IL-6
in culture medium after 4 h incubation as 
determined by an ELISA kit (Invitrogen) are 
shown in (b) and a time course is shown in (c). * 
indicate significant increase of IL-6 released to 
culture medium compared to untreated. 3
indicates significant increase compared to other 
group (ANOVA test, P<0.05). The medium with 
histones collected from above cultures at 16 h 
was passed through an anti-histone scFv 
sepharose column to eliminate most of histones 
and the pass through was added into Hep 2B 
(ATCC) cell culture to induce CRP production. 
The CRP in the medium was detected using 
ELISA kit and is shown in (d). * indicate that 
CRP was significantly produced and released 
from 8 h. (e) the IL-6 in the plasma of mice 
(n=10) before and after injection of 50 mg/kg 
histones. Mean±SD are shown. * indicate 
significant increases from 1 h after injection.   (f) 
the IL-6 in the plasma of mice (n=10) before and 
4 h after trauma. (g) an example of flow 
cytometry analysis of peripheral  blood from 
healthy donors using rat IgG-PE (black, class 
control), rat anti-human IL-6 PE (blue), and anti-
CDs FITC (purple, R1, anti-CD15; R2, anti-
CD14; R3, anti-CD3 corresponding to the gates 
R1, R2 and R3 to represent neutrophils, 
monocytes and lymphocytes, respectively). (h) 
An example of immunohistochemical staining of 
a lung section from a normal mouse with anti-
IL-6 antibody (Abcam). This staining could be 
blocked by pre-incubation of the antibody with 
IL-6 protein. Red arrow indicates the positive 
staining of bronchi epithelial cells and black 
arrow indicates positive staining of blood cells. 
(i) the diagram of the proposed feedback loop. 






